https://www.biopharmadive.com/news/epicrispr-fshd-series-b-financing-epigenetic-editing/743366/
Epicrispr banks $68M to test epigenetic editing on rare muscle disease | BioPharma Dive
The startup is using CRISPR tools to stop errant expression of a gene linked to facioscapulohumeral muscular dystrophy, a disorder on the radars of several...
epigenetic editingmuscle diseasebiopharma divebankstest